Clinical Trials for Multiple Myeloma

201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Phase III Principal Investigator Vij, Ravi…

201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year…

201907148

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn…

202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and…

202012001

A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Acute Myeloid…

201102270

Tissue Acquisition for Genomic and Proteomic Analysis of Plasma Cell Dyscrasias Phase N/A Principal Investigator Vij, Ravi Disease Site Multiple Myeloma

201509025

Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies Phase N/A Principal Investigator Vij, Ravi Disease Site Multiple Myeloma

201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Phase III Principal Investigator Vij, Ravi…

201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year…

201901003

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study…

201905012

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…

201907148

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn…

201907150

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) Phase III…

201910194

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911061

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911163

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Phase III Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and…

202009027

A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma Phase I Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202011140

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma Phase I Principal Investigator Schroeder, Mark Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202012001

A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Acute Myeloid…

202012040

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma…

202103090

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…

202105159

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkins Lymphoma or Multiple Myeloma Phase I/II (Cancer Control) Principal Investigator Mehta-Shah, Neha Disease Site Multiple Myeloma;…